Peringatan Keamanan

Symptoms of overdose include drowsiness, weakness, inco-ordination, difficulty with micturition, respiratory depression, hypotension, agitation, irritability, convulsions, hypertension, palpitation and tachycardia.

Triprolidine

DB00427

small molecule approved

Deskripsi

First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.

Struktur Molekul 2D

Berat 278.3914
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 4 to 6 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly absorbed in the intestinal tract.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid alcohol. Taking with alcohol may increase drowsiness.

Interaksi Obat

957 Data
Buprenorphine Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
Hydrocodone Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Triprolidine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Triprolidine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
Mirtazapine Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
Orphenadrine Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
Pramipexole Triprolidine may increase the sedative activities of Pramipexole.
Ropinirole Triprolidine may increase the sedative activities of Ropinirole.
Rotigotine Triprolidine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Triprolidine.
Sodium oxybate Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
Thalidomide Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Benzylpenicilloyl polylysine Triprolidine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Triprolidine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Triprolidine.
Ethanol Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
Fluvoxamine The risk or severity of adverse effects can be increased when Triprolidine is combined with Fluvoxamine.
Duloxetine The risk or severity of adverse effects can be increased when Triprolidine is combined with Duloxetine.
Paroxetine The risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Triprolidine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Triprolidine is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Triprolidine is combined with Nefazodone.
Zimelidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Triprolidine is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Triprolidine is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Triprolidine is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Triprolidine is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Triprolidine is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Triprolidine is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Triprolidine is combined with Alaproclate.
Citalopram The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Citalopram.
Escitalopram The risk or severity of adverse effects can be increased when Triprolidine is combined with Escitalopram.
Amphetamine Amphetamine may decrease the sedative activities of Triprolidine.
Phentermine Phentermine may decrease the sedative activities of Triprolidine.
Benzphetamine Benzphetamine may decrease the sedative activities of Triprolidine.
Diethylpropion Diethylpropion may decrease the sedative activities of Triprolidine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Triprolidine.
Mephentermine Mephentermine may decrease the sedative activities of Triprolidine.
MMDA MMDA may decrease the sedative activities of Triprolidine.
Midomafetamine Midomafetamine may decrease the sedative activities of Triprolidine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Triprolidine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Triprolidine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Triprolidine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Triprolidine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Triprolidine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Triprolidine.
Metamfetamine Metamfetamine may decrease the sedative activities of Triprolidine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Triprolidine.
Ritobegron Ritobegron may decrease the sedative activities of Triprolidine.
Mephedrone Mephedrone may decrease the sedative activities of Triprolidine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Triprolidine.
Gepefrine Gepefrine may decrease the sedative activities of Triprolidine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Triprolidine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Triprolidine.
Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Triprolidine.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Triprolidine.
Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Triprolidine.
Cyproheptadine The risk or severity of CNS depression can be increased when Triprolidine is combined with Cyproheptadine.
Imipramine The risk or severity of CNS depression can be increased when Triprolidine is combined with Imipramine.
Nortriptyline The risk or severity of CNS depression can be increased when Triprolidine is combined with Nortriptyline.
Amoxapine The risk or severity of CNS depression can be increased when Triprolidine is combined with Amoxapine.
Nicardipine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Nicardipine.
Propiomazine The risk or severity of CNS depression can be increased when Triprolidine is combined with Propiomazine.
Maprotiline The risk or severity of CNS depression can be increased when Triprolidine is combined with Maprotiline.
Tolterodine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Tolterodine.
Doxepin The risk or severity of CNS depression can be increased when Triprolidine is combined with Doxepin.
Desipramine The risk or severity of CNS depression can be increased when Triprolidine is combined with Desipramine.
Solifenacin The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Solifenacin.
Pizotifen The risk or severity of CNS depression can be increased when Triprolidine is combined with Pizotifen.
Trimebutine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Trimebutine.
Dosulepin The risk or severity of CNS depression can be increased when Triprolidine is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Triprolidine is combined with Zopiclone.
Leuprolide The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Goserelin.
Erythromycin The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Azithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Moxifloxacin.
Ranolazine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ranolazine.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Sulfisoxazole.
Diltiazem The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Diltiazem.
Nimodipine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Nimodipine.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Triprolidine.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ciprofloxacin.
Fluorouracil The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Fluorouracil.
Perflutren The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Perflutren.
Cinnarizine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Cinnarizine.
Atropine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Atropine.

Target Protein

Histamine H1 receptor HRH1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 2568212
    Mann KV, Crowe JP, Tietze KJ: Nonsedating histamine H1-receptor antagonists. Clin Pharm. 1989 May;8(5):331-44.
  • PMID: 7913608
    Simons FE: H1-receptor antagonists. Comparative tolerability and safety. Drug Saf. 1994 May;10(5):350-80.
  • PMID: 2866055
    Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97.
  • PMID: 3620284
    Telekes A, Holland RL, Withington DA, Peck AW: Effects of triprolidine and dipipanone in the cold induced pain test, and the central nervous system of healthy volunteers. Br J Clin Pharmacol. 1987 Jul;24(1):43-50.

Contoh Produk & Brand

Produk: 124 • International brands: 2
Produk
  • Actifed DM Syrup
    Syrup • - • Oral • Canada • OTC • Approved
  • Actifed DM Syrup
    Syrup • - • Oral • Canada • OTC • Approved
  • Actifed DM Tablets
    Tablet • - • Oral • Canada • OTC • Approved
  • Actifed DM Tablets
    Tablet • - • Oral • Canada • OTC • Approved
  • Actifed Plus Caplet
    Tablet • - • Oral • Canada • OTC • Approved
  • Actifed Plus Caplets
    Tablet • - • Oral • Canada • OTC • Approved
  • Actifed Syrup
    Liquid • - • Oral • Canada • OTC • Approved
  • Actifed Tablets
    Tablet • - • Oral • Canada • OTC • Approved
Menampilkan 8 dari 124 produk.
International Brands
  • Anmin — AND
  • Venen — Sato Seiyaku

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul